Loading patent…
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsSujan Shresta, Lauren Yauch, Alessandro Sette, Daniela Weiskopf
Estimating the term…
Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, an adjuvant and a peptide consisting of a sequence 9-25 amino acids in length wherein 9 contiguous amino acids are identical to VATTFVTPM (SEQ ID NO:134), wherein the peptide elicits, stimulates, induces, promotes, increases, or enhances an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response, wherein the adjuvant is present in an amount that increases immunogenicity of the peptide.
Dependencies are inferred from the claim text.